The 340B Program is a pharmaceutical subsidization program enacted in 1992 aimed towards allowing safety-net hospitals and clinics to better stretch their limited resources to serve uninsured and/or low-income patients. With its rapid growth, the 340B program has faced scrutiny in regards to its levels of efficacy and integrity. This report aims to analyze academic literature related to instances of 340B enactment across the United States and evaluate the extent to which it has accomplished its original objectives in three main areas: drug access, financial effects, and healthcare quality. We conducted a comprehensive literature review utilizing Google Scholar primarily to explore these three aspects in the context of the 340B Program.
No takes yet. Share an insight, caveat, or question.
Gangireddy et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: